The scientific consensus is clear. Over-the-counter (OTC) ibuprofen/Advil remains safe to use as directed. The current scientific literature does not show that OTC ibuprofen/Advil makes COVID-19 health outcomes worse, and the world’s leading health authorities have confirmed there is no evidence to recommend that COVID-19 patients avoid OTC ibuprofen.
The use of NSAIDs [like ibuprofen] does not lead to more severe coronavirus outcomes.
In this study of 9,236 Danish residents who tested positive for COVID-19 between February 27th and April 29th, 2020, the use of NSAIDs [like ibuprofen] within 30 days of the positive test was not associated with an increased risk of hospitalization, ICU admission, mechanical ventilation, & renal replacement therapy or mortality.
Lund LC, Kristensen KB, Reilev M, et al. PLoS Med. 2020;17(9):e1003308. Published 2020 Sep 8. doi:10.1371/journal.pmed.1003308
Journal of Clinical Medicine Study: August 10, 2020
No evidence that routine NSAID use was associated with higher COVID-19 mortality This [multicentre, prospective, observational study of 1,222 adult patients hospitalised with COVID-19 in eight UK hospitals] found no evidence that routine NSAID use was associated with higher COVID-19 mortality… & therefore, patients should be advised to continue taking these medications until further evidence emerges.”
Bruce E, Barlow-Pay F, Short R, Vilches-Moraga A, Price A, McGovern A, Braude P, Stechman M, Moug S, McCarthy K, Hewitt J, Carter B, Myint P. J Clin Med. 2020 Aug 10;9(8):E2586.
Clinical Microbiology and Infection Study: June 12, 2020 Ibuprofen use not associated with worse clinical outcomes from COVID-19 In this [retrospective cohort study of 403 patients with COVID-19 from Shamir Medical Centre, Israel] ibuprofen use was not associated with worse clinical outcomes, compared with paracetamol [acetaminophen]. In patients with fever, there was no difference in clinical outcomes between ibuprofen and paracetamol [acetaminophen] users. Rinott E, Kozer E, Shapira Y, Bar-Haim A, Youngster I. Clin Microbial Infect, 2020 Jun 12; S1198-743X(20)30343-8. Learn More
Chest Study in Vancouver, BC, Canada: March 2020
Current evidence is not strong enough to infer a causal link of a harmful effect of ibuprofen in patients with COVID-19
An early study in Vancouver, BC, Canada, concluded that the current epidemiologic evidence is not strong enough to infer a causal link of a harmful effect of ibuprofen in patients with COVID-19, and we need to be cautious when drawing conclusions from evidence that is derived from mechanistic or theoretical pharmacology, as they are not always corroborated with data from clinical trials.
Sodhi M, Etminan M. Safety of Ibuprofen in Patients With COVID-19: Causal or Confounded?. Chest. 2020;158(1):55-56. doi:10.1016/j.chest.2020.03.040]
Adding Research Publications to What We Know About Advil (Ibuprofen) and COVID-19 – September 23, 2020Learn More
By clicking the link(s) above, you will be taken to an external website that is independently operated and not managed by Haleon. Haleon assumes no responsibility for the content on the website. If you do not wish to leave this website, do not click on the links above.
American Headache Society, July 2020
There is no specific evidence at this time against the use of NSAIDs in patients with or without COVID‐19
A recent study, published in Headache in July 2020, concluded that there is no specific evidence at this time against the use of NSAIDs in patients with or without COVID‐19. Authors recommend a patient should be assessed for any other chronic diseases, underlying or pre-existing illnesses or conditions (i.e., co-morbid medical conditions) that may limit the use of NSAIDs and recommend a discussion of risks and benefits with all patients prior to prescribing NSAIDs.
Arca KN, Smith JH, Chiang CC, et al. COVID-19 and Headache Medicine: A Narrative Review of Non-Steroidal Anti-Inflammatory Drug (NSAID) and Corticosteroid Use [published online ahead of print, 2020 Jul 10]. Headache. 2020;10.1111/head.13903. doi:10.1111/head.13903]
Clinical Infectious Disease Study: July 27, 2020
Observational study reviews risk of prescription-strength NSAID use by hospitalized COVID-19 patients
An observational study from South Korea suggested that the harms associated with NSAID use may outweigh their benefits for patients with COVID-19; however, researchers looked only at patients hospitalized with COVID-19 who were prescribed prescription-strength, not OTC NSAIDs, and it is unclear if the prescribed NSAIDs were part of their COVID-19 treatment course or for one or more underlying serious health conditions.
Jeong HE, Lee H, Shin HJ, Choe YJ, Filion KB, Shin JY. Clin Infect Dis. 2020 Jul 27:ciaa1056. doi: 10.1093/cid/ciaa1056. Epub ahead of print. PMID: 32717066; PMCID: PMC7454423.
No overall increased risk of COVID-19 related death associated with current prescribed NSAID use.
In two similarly designed studies, researchers studied prescribed NSAID users and non-users and “..found no evidence of a harmful effect of routinely prescribed NSAIDs on COVID-19 related death.” They separately evaluated a general population (Study 1) and a population with rheumatoid arthritis or osteoarthritis (Study 2); NSAID users and nonusers did not have a difference in risk for COVID-19 related deaths when adjusted for differences between them in the two study populations. The researchers conclude that “...people currently prescribed NSAIDs for their long-term conditions should continue their treatment as part of their routine care.”
Wong AYS, et al. Ann Rheum Dis 2021;0:1–9. doi:10.1136/annrheumdis-2020-219517